02 Feb 2016

Revlimid (Lenalidomida) - Portugal

ATC: L04AX
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
OTHER IMMUNOSUPPRESSANTS
Revlimid

Last Updated on 02 Feb 2016 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

Revlimid Indication

Mieloma múltiplo
Revlimid é indicado para o tratamento de doentes adultos não elegíveis para transplante com mieloma múltiplo sem tratamento anterior.

Revlimid em combinação com a dexametasona é indicado para o tratamento de doentes adultos com mieloma múltiplo que tenham recebido pelo menos um tratamento anterior.

Síndromes mielodisplásicas
Revlimid é indicado para o tratamento de doentes com anemia dependente de transfusão causada por síndromes mielodisplásicas de baixo risco ou de risco intermédio 1 associadas a uma anomalia citogenética por deleção de 5q isolada quando outras opções terapêuticas são insuficientes ou inadequadas.

 

Revlimid Generic Name

Lenalidomida

Type

POM

Summary Product Characteristics (SPCs) Links
Resumo das Características do Medicamento - Revlimid (external site)

Related Learning Zones

Prostate Cancer Learning Hub

Prostate Cancer Learning Hub

The Prostate Cancer Learning Hub has been designed with the busy healthcare professional in mind. The resource conveniently organises a range of up-to-date education content, reference materials and decision support tools, all focussing on prostate cancer. The disease awareness section provides you with access to a Prostate Cancer Knowledge Centre, which has been developed to provide you with easy to digest best practice guidance for the treatment and management of patients with prostate cancer.

Oral Anticoagulation Reversal Knowledge Centre

Oral Anticoagulation Reversal Knowledge Centre

The Oral Anticoagualtion Reversal Knowledge Centre is intended to provide healthcare professionals with accurate information on the approaches to oral anticoagulation reversal for patients who experience or are at risk of significant bleeding, or require surgery. Content is arranged within illustrated and referenced sections including management of bleeding risk, oral anticoagulants, symposium highlights, key publication summaries and more.

This resource is developed by EPG Health Media (Europe) Ltd for epgonline.org in collaboration with CSL Behring, with content provided by CSL Behring.

This resource is not intended for healthcare professionals outside Europe.

Selected content related to Revlimid (Lenalidomida)

Clinical Trials

Journals

  • The evolving role of lenalidomide in non-Hodgkin lymphoma.
    Galanina N, Petrich A, Nabhan C.
    Leukemia & Lymphoma Feb 2016

    Recent advances in the treatment of patients with non-Hodgkin lymphoma have driven a paradigm shift from standard chemotherapy to an ever-expanding choice of targeted agents and combinations. As an orally
     

  • Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
    Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A et al.
    The New England Journal of Medicine Jan 2015

    Background: Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1
     

News

Guidelines

Revlimid Warnings

Este medicamento está sujeito a monitorização adicional. Isto irá permitir a rápida identificação de nova informação de segurança. Pede-se aos profissionais de saúde que notifiquem quaisquer suspeitas de reações adversas.

Revlimid Marketing Information

Revlimid Generic Name
Lenalidomida
Marketing Company
Celgene Europe Ltd
Drug Type
POM
Date of Issue, Marketing Authority

14/06/2007

Related Drugs - Oncology

Back to top